failed to demonstrate a regenerative activity, particularly of haematopoietic stem cells, despite a clear functional improvement. An improvement of neovascularisation and the release of growth factors and cytokines by stem and progenitor cells influencing scar formation are talked about by cardiologists and scientists as alternate or additional mechanisms by which stem cell therapy exerts a functional benefit.
Based on experimental studies, clinical phase I studies were started in 2001. The infusion or injection of cells that were isolated from the bone marrow increased the regional or global ejection fraction, and/or reduced infarct size and endsystolic volume expansion, in pilot trials, randomised trials, and a recent multicentre study with more than 200 patients (see Table below ). Interestingly, all the pilot clinical trials in patients with acute myocardial infarction, as well as the subsequent randomised trials, were carried out in Europe.
Why is this the case? Actually, this should not come as too much of a surprise. Europe has a long history of the clinical development of novel interventional regimes in cardiology -it is sufficient just to mention the development of percutaneous coronary intervention and stent implantation. However, it research in humans is the lack of an "FDA-like Agency" in Europe. On the contrary, I assume the same capacity and power of imagination among American and European researchers. Therefore, from my point of view, the main difference between Europe and the United States in terms of clinical stem cell work could be the different organisation of health services. On the one hand, in Spain, as in the rest of Europe, all health requirements are free and covered by national governments. On the other hand, all university hospitals and other hospitals that are centres of excellence belong to the national health systems.
Furthermore, almost every cardiology department has a hierarchical organisation with all the critical units (interventional cardiology, coronary units, etc) under the same umbrella. Although it should be admitted that this model has many weaknesses, it is also clear that it makes the organisation (local level, networks) of clinical research in general, and stem cell clinical research in particular (selection and recruitment of patients, intra-and interhospital coordination, follow-up logistics, in particular regarding imaging studies, etc), much easier.
Hein Wellens, MD, emeritus professor of cardiology, University of Maastricht, has made this institution an internationally famous centre for the study of arrhythmias. He discusses his career with Robert Short, BSc.
The opinions expressed in Circulation: European Perspectives in Cardiology are not necessarily those of the editors or of the American Heart Association. 
What do you consider your main contributions to the field?
I see my major contribution to be the training of other cardiologists throughout the world in the study and treatment of arrhythmias. This work goes on, despite my retirement. But other people see "programmed electrical stimulation of the heart" as my major contribution. This was a result of work done in the late 1960s in Amsterdam, when Rein Schuilenburg, MD, and myself studied a patient who had Wolff-Parkinson-White syndrome. We placed catheters in different sites in the heart.
This allowed us to locate the origin of the arrhythmia by recording the spread of cardiac activation during an arrhythmia, and, furthermore, the connection of these catheters to a pacing device allowed us to initiate and terminate the arrhythmias. Also in 1967, independently of the group in Amsterdam, Philippe Coumel, MD, FESC, of the Hôpital Lariboisière, Paris, France and his colleagues published an article that described this technique. 1 Programmed electrical stimulation was soon used for analysis of other cardiac arrhythmias apart from Wolff-Parkinson-White syndrome to diagnose the origin and mechanism of the arrhythmia. By carefully analysing the ECGs in stimulation studies, new ways were developed to make it a reliable, noninvasive tool to study the site of origin of an arrhythmia. Later, through the work of people from all over the world, the information provided by stimulation studies was the basis for therapeutic approaches -for example, antitachycardia pacing, and curative approaches such as surgical ablation, and, later, catheter ablation procedures.
Was there a major turning point in your career?
Yes. After working for many years in Amsterdam with Dr Durrer, it became clear that our ideas now differed about what research should be given priority to advance cardiology. So I moved in 1977 to the new University of Limburg in Maastricht as professor of cardiology. My task was to start academic cardiology there from scratch. I had one cardiologist who I brought along from Amsterdam, Frits Bär, MD. And I had one fellow in cardiology who I was training, Anton Gorgels, MD, and this small group was the start of academic cardiology in Maastricht.
After several difficult years, things started to progress. A Fellow from Madrid, Jerónimo Farré, MD, of the Fundacion Jiménez Díaz, Madrid, Spain, played a crucial role in getting the antiarrhythmia activities moving.
Year by year an increasing number of people came from all over the world to learn to use programmed electrical stimulation.
I cannot over-stress the role the Fellows from abroad played. These young people were energetic, motivated, and contributed enormously to shaping the group, to research, and to the scientific output.
Interest has snowballed, and Maastricht is now an internationally acclaimed centre for the study of arrhythmias. I have had the good fortune to train over 130 enthusiastic young people from abroad in the study and treatment of cardiac arrhythmias. They have taken this knowledge and enthusiasm back to their own countries. I consider this to be my main contribution to my field.
What of the future?
Unfortunately, the most influential person in my career recently has been Bismarck. Otto von Bismarck (German Chancellor 1862-1890) designed the world's first social insurance program in 1889 and stipulated a retirement age. A commonly held myth is that he set the retirement age at 65. I think 65 is, nowadays, an age at which many of us are still able to be productive. Indeed, Bismark set the retirement age at 70, when he himself was 74. Only in 1916 was the age lowered to 65.
So now I teach a lot, write books, and give courses. This year we will have the 25th anniversary of the cardiology arrhythmia course I give with the American arrhythmia giant Mark Josephson, MD, professor and head of cardiology at the Beth Israel Deaconess Medical Center, Boston, Mass. Almost all the Americans active in the field of cardiac arrhythmias have attended the course. I give that course on both sides of the Atlantic a couple of times a year.
I am still much involved in cardiology and in giving advice. One of the challenges is how to reduce sudden deaths out of hospital. I am trying to get people interested in developing a device that a person can wear that will register cardiac activity continuously, give an immediate diagnosis of sudden cardiac arrest (SCA), sound an audible alarm to alert a bystander, and transmit the location of the victim to the nearest emergency service (see Figure, where his father, Wilhelm His, Sr, MD, was the professor of anatomy. In 1872 his father was called to the University of Leipzig and His, Jr became a student at the city Gymnasium, an important centre of academic learning.
At that time, Leipzig was the centre of culture in southern Germany, and the young Wilhelm's education was enhanced by his exposure to music and the arts. His mother was a gifted musician, and His, Jr became a proficient violinist and also a talented painter. His final 2 Gymnasium years were spent in Basle, which afforded him a good command of French.
He later studied at the universities of Geneva, Strasbourg, Bern, and Leipzig, graduating from Leipzig in 1888 and receiving his medical degree in 1889. As a student at Strasbourg, His studied under the renowned chemical and pharmacological teacher, Oswald Schmiedeberg, MD, and was introduced to the processes of metabolism. The results of his research into the chemical changes of pyridine were published in 1886. 1 In 1889, Dr His was appointed assistant in the medical clinic at Leipzig under Heinrich Curschmann, MD, where it became evident that his well-developed knowledge of chemistry and anatomy was beyond that of most young clinicians. In 1893, a small volume entitled "Work from the medical hospital of Leipzig" was published from the clinic, and included his first observations concerning the atrioventricular (AV) bundle of the heart, an embryonic muscle bundle uniting the right auricle with the ventricles. This was later known eponymously as "the bundle of His." The circulation of the volume was limited and, unfortunately, as Dr His pointed out many years later, "very few people read the article." 2(p170) Dr His was primarily a clinician rather than an anatomist. His only anatomical studies were those relating to the AV conduction bundle, and with his appointment in 1895 to the post of assistant professor of clinical medicine, his interest turned to work on gout and diseases of the joints -a branch of medicine destined to fill his long clinical and teaching career.
During the First World War, Dr His was appointed to a specially created post of "consulting internist," and he spent most of his time on the Eastern front. He was the first to describe trench fever, which he named "Volhynia fever," after a district in Russia. In 1931, Dr His published his war memoirs in a book entitled A German Doctor at the Front, 3 pointing out that "there is justification for the narrative of one who travelled much, who has seen much, and who has pursued his medical labours in all possible situations." 2(p180) Interestingly, in several of his works Dr His was an advocate of moderate eugenics, but he was never an anti-Semite or Nazi sympathiser. After the war, Dr His returned to Berlin, where he resumed the post of professor of internal medicine and director of the first medical clinic at the Charité. In 1932, suffering from emphysema, he retired to Brombach in South Baden, Germany, and died in Basle some two years later.
During his retirement, he published his final scientific and historic account of the structure and function of the AV bundle. 4 In 1907, Sir Arthur Keith, MD, a lecturer in anatomy at the London Hospital Medical School, and Martin William Flack, MA, MB, BS, also of the London Hospital, discovered a small area of tissue, later known as the Keith-Flack or sinoauricular node, in the right ventricle. They thought this was probably the "pacemaker" of the heart. Two years later this conjecture was proved correct by Sir Thomas Lewis, MD, (1881-1945) of University College, London.
In his paper of 1933, a year before his death, Dr His generously discussed the question of priority for the discovery of the AV bundle, but the eponymous honour remains with the man described by a colleague as "a master of his profession, a great physician, and a well-cultured gentleman." 2(p182) Circulation: European Perspectives f72 Circulation May 9, 2006
